First-in-class iberdomide has been given accelerated approval under the Zenbexus brand name, alongside Johnson & Johnson and ...

Skylark Bio has started dosing patients in a phase 1/2 trial of SKY-GJB2, a one-shot gene therapy designed to treat ...

Just a few weeks after filing for bankruptcy protection, Sangamo Therapeutics has found buyers for some of its key assets, including a Fabry disease therapy and its genomic medicine platforms. PTC ...

Indeed, GLP-1 therapies currently bring with them the inconvenience of subcutaneous injections, the difficulty of titration, ...

June and July delivered a busy stretch of leadership moves across pharma and biotech. From major R&D appointments at large drugmakers to a wave of CEO, CMO, and commercial hires across emerging ...

Actio is the third acquisition for Jazz in the last few years, coming after it bought Chimerix for $935 million last year and ...

AbbVie, Bristol Myers Squibb, and Novartis have filed separate lawsuits in Illinois, each seeking to overturn a recently ...

England is one of a handful of countries globally to have already exceeded the WHO benchmark of treating 80% of all known ...

Ex-BioNTech chief strategy officer Ryan Richardson is chief executive of the new outfit, which launches with $25 million in ...

Takeda's orexin agonist Orzeyful has been approved in the US to treat narcolepsy type 1 (NT1) in adults, becoming the first ...

Pathos AI has added to its pipeline of cancer drugs by licensing a bispecific antibody-drug conjugate (ADC) for solid tumours ...